Vaccino MPR: la storia non si cancella!

Lo scorso mese di febbraio 2012 è uscita una nuova revisione della Cochrane sul vaccino MPR  le cui conclusioni rappresentano il lavaggio delle mani e della coscienza in merito ai danni provocati da questo vaccino trivalente a virus vivi attenutati: “il design e la comunicazione dei risultati di sicurezza negli studi del vaccino MMR, pre- e post-marketing, sono in gran parte inadeguate. Le prove degli eventi avversi dopo vaccinazione con il vaccino MMR non possono essere separate dal suo ruolo nella prevenzione delle malattie a cui è destinato“.

Proseguire a dichiarare sicuro un vaccino che non lo è affatto, il più grande scandalo della medicina moderna, è decisamente antipatico dal punto di vista sanitario per i danni che genera alla salute dei bambini e anche per i danni di immagine che suscita nei genitori nei confronti del Servizio Sanitario Nazionale.

Dopo la recente sentenza del Tribunale di Rimini [alla quale potrebbe aggiungersi presto un altro caso] che è tornata ad associare la vaccinazione anti Morbillo-Parotite-Rosolia [MPR] all’Autismo, e conseguente alzata di scudi da parte di varie Federazioni di Igiene e Pediatria, ben agisce il Tribunale del Malatonel pieno rispetto di una scelta consapevole,  affermando che “i genitori abbiano invece il diritto di avere informazioni certe sui possibili rischi [avvalorati da ricerche scientifiche valide]“.

Il primo caso eclatante risale al 1986, anno in cui in Canada venne isolato nel vaccino TRIVIRIX il pericoloso ceppo URABE AM-9 che si rese responsabile di alcuni casi di meningite post vaccinica come riportato dallo studio Champagne et al. Can Dis Weekly Rep. 1987;13:155-157. Nel 1987 il TRIVIRIX viene ritirato dal mercato.

Nel 1988 The Lancet pubblica, nel Volume 2 di luglio, l’articolo Mumps meningitis following measles, mumps, and rubella immunisation a seguito dei vari casi di reazioni avverse che occorsero in Canada, Regno Unito e Giappone.

Nel 1990 la licenza del TRIVIRIX venne revocata in Canada, Malysia, Philippine, Singapore e Australia.

Nel settembre 1992 la SmithKline Beecham [l’attuale GSK] obbliga uno stop urgente del  vaccino PLUSERIX utilizzato nel Regno Unito. Inoltre, altissimi rischi di reazioni anafilattiche vengono riportate negli Stati Uniti e pubblicati nello studio Allergic reactions to MMR vaccine  niente di meno che da PEDIATRICS [la stessa rivista che, ricca di contraddizioni, a settembre 2010 dichiara che il Mercurio è scientificamente sano ].

Sempre a settembre del 1992 entra in gioco il famoso vaccino MMR II della Merck Sharp & Dhome in sostituzione del sopra citato PLUSERIX e del IMMRAVAX.

La vaccinazione con i vaccini antiparotite  contenenti il ceppo URABE AM-9 è stata associata alla comparsa di casi di meningite asettica. L’incidenza riportata in letteratura è molto variabile: 1 caso ogni 2.000 dosi, 6 casi ogni 2.000 dosi, 1 caso ogni 3.800 dosi.

In Giappone, uno studio ha riportato 49 casi di meningite asettica ogni 100.000 dosi di ceppo URABE AM-9 prodotto localmente [Ueda K, Miyazaki C, Hidaka Y, et al. Aseptic meningitis caused by measles, mumps, rubella vaccine in Japan. Lancet 346: 701-702, 1995]. Uno studio successivo ha riportato un incidenza di 100 casi ogni 100.000 dosi [Sugiura et al. Aseptic meningitis as a complication of mumps vaccination. Pediatric Infectious Disease Journal 10: 209-213, 1991]. I dati giapponesi suggeriscono che non tutti i ceppi Urabe AM-9 abbiano lo stesso profilo di reattogenicità. Infatti, uno studio prospettico di sorveglianza dopo vaccinazione con quattro diversi prodotti MPR contenenti il ceppo URABE AM-9 hanno mostrato che l’incidenza di meningite asettica confermata virologicamente variava da 0 a 170 casi per 100.000 a seconda del prodotto [Kimura M, Kuno-Sakai H, Yamazaki S et al. Adverse events associated with MMR vaccines in Japan. Acta Paediatr Jpn, 1996 Jun;38(3):205-11]. In Giappone i vaccini MPR, che contenevano tutti il ceppo URABE AM-9, sono stati ritirati nel 1993.

 La realtà italiana

In Italia negli anni ’90 sono stati presenti sul mercato vaccini contenenti ceppo URABE AM-9 [Pluserix della ditta SKB, Morupar della Ditta Sclavo-Chiron, Vaxipar della ditta Sclavo-Chiron] e vaccini contenenti il ceppo RUBINI [Triviraten della ditta Berna].

Poi sono stati introdotti sul mercato vaccini contenenti il ceppo Jeryl Lynn [MMRII della ditta Aventis Pasteur, anno di registrazione 1994] e il ceppo RIT-4385, derivato dal Jeryl Lynn [Priorix della ditta Glaxo Smith Kline, anno di registrazione 1998, contenente cellule di feti abortiti].

Il vaccino Pluserix fu ritirato dalla ditta produttrice nel 1992, come accennavo in precedenza, a seguito delle osservazioni provenienti dal Regno Unito, mentre il ceppo Rubini è stato ritirato dal commercio nel 2001, data la sua scarsa efficacia.

Fino al 2003 il ceppo URABE AM-9 si trovava in commercio in Italia come vaccino monovalente [Vaxipar della Chiron] e come vaccino trivalente morbillo-parotite-rosolia [Morupar della Chiron]. Da sottolineare che la quantità di virus nei preparati Morupar e Vaxipar era di 4 volte inferiore a quella contenuta nel Pluserix [5.000 TCID50 rispetto a 20.000 TCID50]. Inoltre si affermava che il ceppo URABE prodotto dalla Chiron aveva una maggiore stabilità genetica rispetto al ceppo URABE prodotto dalla Smith Kline Beecham [Amexis G, Fineschi N, Chumakov K. Correlation of Genetic Variability with safety of Mumps Vaccine Urabe AM9 strain. Virology 2001 Aug; 287(1):234-41].

Malgrado l’intensa campagna vaccinale in atto i dati forniti dalla farmacovigilanza sono sempre incompleti [pessimo fenomeno di under-reporting generato da malcostume], al 2011 sembrano aumentati i casi di morbillo malgrado questa vaccinazione è proposta a tappeto da parecchi anni [dai 3.065 segnalati nel 2010 si è passati ai 4.600 nel 2011 con un aumento percentuale di quasi il 50% da un anno all’altro, forse c’è qualche problema di affidabilità???] e si prosegue a chiamare autismo [diagnosi esclusivamente comportamentale] ciò che, in bambini predisposti dal punto di vista immunitario, è a tutti gli effetti una encefalopatia post vaccinica [diagnosi biologica].

Attualmente, oltre al sopra citato Priorix, vi sono in commercio anche 2 vaccini tetravalenti [Morbillo Parotite Rosolia Varicella – Priorix Tetra e Proquad] che hanno richiamato l’attenzione oltre il livello di guardia da parte del Working Group Pediatrico dell’AIFA. E’ stato stimato che nei bambini tra 12-23 mesi di età si hanno da 7 a 9 casi di convulsioni febbrili ogni 10.000 bambini vaccinati con vaccino tetravalente [Morbillo Parotite Rosolia Varicella] e 3-4 casi ogni 10.000 bambini vaccinati con il vaccino trivalente [Morbillo Parotite Rosolia] e il vaccino monovalente Varicella somministrati separatamente. In pratica, non solo è atteso un caso in più di convulsione febbrile ogni 2300-2600 bambini vaccinati dopo vaccinazione con MPRV rispetto alla somministrazione separata di MPR e V, ma viene confermato indirettamente che il vaccino trivalente MPR prosegue ad essere insicuro. 

Per coloro che promuovono calendari vaccinali da 0 a 100 anni questi numeri sono insignificanti, a tal punto da organizzare ampie offensive mediatiche. C’è da chiedersi se queste persone sono dotate di dignità umana e di buon senso: considerato che ancora oggi proseguono a screditare una massa di genitori in grandissima difficoltà, definendoli in modo irrispettoso e dispregiativo “attivisti anti-vaccinali, talebani, dissidenti“.

C’è da chiedersi se queste persone sono dotate di dignità umana, di buon senso e professionalità quando è possibile elencare un’ampia bibliografia, probabilmente dimenticata in qualche soffitta da parte di questi promotori vaccinali [allineati a ordini di scuderia che alimentano Il segreto delle procedure riguardanti il sistema regolatorio dei farmaci], che dimostra come il vaccino MPR non è assolutamente esente da rischi [talvolta molto gravi].

Bibliografia

Vaccino MPR e disturbi neurologici
[compresi danni del Sistema Nervoso Centrale, Panencefalite Subacuta sclerosante, Sindrome di Guillain Barré]

  • Bottiger, M., et al. “Swedish experience of two dose vaccination programme aiming at eliminating measles, mumps and rubella.” British Medical Journal 1987; 295:264-67.
  • Thomas, E. “A case of mumps meningitis: A complication of vaccination?” Journal of the Canadian Medical Association 1988; 138:135.
  • Champagne, S., et al. “A case of mumps meningitis: a post-immunization complication?” Canadian Disease Weekly Report 1988; 13-35:155-156.
  • Ehrengut, W. “Mumps vaccine and meningitis.” Lancet 1989; 2:751.
  • Von Muhlendahl, K.E. “Mumps meningitis following measles, mumps and rubella immunisations.” Lancet (August 12, 1989), p. 394.
  • Cizman, M., et al. “Aseptic meningitis after vaccination against measles and mumps.” Pediatric Infectious Disease Journal 1989; 8:302-308.
  • McDonald, J., et al. “Clinical and epidemiological features of mumps meningo-encephalitis and possible vaccine-related disease.” Pediatric Infectious Disease Journal (November 1989), pp. 751-754.
  • Gray, J.A., et al. “Mumps meningitis following measles, mumps, and rubella immunisation.” Lancet 1989; i:98.
  • Gray, J.A., et al. “Mumps vaccine meningitis.” Lancet 1989; i:927.
  • Murray, M.W., et al. “Mumps meningitis after measles, mumps, and rubella immunisation.” Lancet 1989; ii:877.\
  • “Mumps meningitis and MMR vaccination.” [Editorial] Lancet 1989; ii:1015-1016.
  • Forsey, T., et al. “Mumps viruses and mumps, measles, and rubella vaccine.” British Medical Journal 1989; 299:1340.
  • Forsey, T., et al. “Mumps vaccines and meningitis.” Lancet 1992; 340:980.
  • Miller, E., et al. “Risk of aseptic meningitis after measles, mumps, and rubella vaccine in U.K. children.” Lancet 1993; 341:979.
  • Sawada, et al. Lancet 1993; 342:371.
  • Schneck, S.A. “Vaccination with measles and central nervous system disease.” Neurology 1968; 18 (Part 2):79-82.
  • Jabbour, J.T., et al. “Epidemiology of subacute sclerosing panencephalitis (SSPE).” Journal of the American Medical Association 1972; 220:959-62.
  • Belgamwar, R.B., et al. “Measles, mumps, rubella vaccine induced subacute sclerosing panencephalitis.” Journal of the Indian Medical Association 1997; 95(11):594.
  • Landrigan, P.J., et al. “Neurological disorders following live measles-virus vaccination.” Journal of the American Medical Association 1973; 223 (13):1459-62.
  • Miller, C.L. Lancet (September 17, 1983).
  • Beale, A.J. “Measles vaccines.” Proceedings of the Royal Society of Medicine 1974; 67:1116-1119.
  • Roden, A.T. “Fits following immunization.” Proceedings of the Royal Society of Medicine 1974; 67:24.
  • Jagdis, F., et al. “Encephalitis after administration of live measles vaccine.” Journal of the Canadian Medical Association (April 19, 1975); 112(8):972-75.
  • Hirayama, M. “Measles vaccines used in Japan.” Reviews of Infectious Diseases 1983; 5:495-503.
  • Pollock, T.M., et al. “A 7-year survey of disorders attributed to vaccination in Northwest Thames Region.” Lancet 1983; 1:753-57.
  • Jorch, G. et al. “Coincidence of virus encephalitis and measles-mumps vaccination.” Monatsschr Kinderheilkd 1984; 132(5):299-300.
  • Martinon-Torres, F., et al. “Self-limited acute encephalopathy related to measles component of viral triple vaccine.” Rev Neurol (May 1-15, 1999); 28(9):881-82.
  • Grose, C., et al. “Guillain-Barre syndrome following administration of live measles vaccine.” American Journal of Medicine 1976; 60:441-43.
  • Norrby, R. “Polyradiculitis in connection with vaccination against morbilli, parotitis and rubella.” Lakartidningen 1984; 81:1636-37.
  • Morris, K., et al. “Guillain-Barre syndrome after measles, mumps, and rubella vaccine.” Lancet 1994; 343:60.
  • Wakefield, A., et al. “Measles, mumps and rubella vaccine: through a glass, darkly.” Adverse Drug Reaction and Toxicologica Reviews2000; 19(4):265-283.
  • Templeton, S. “MMR vaccine should not have been licensed.” Sunday Herald(London: December 10, 2000). [Article]
  • Petrovic, M., et al. “Second dose of measles, mumps, and rubella vaccine: questionnaire survey of health professionals.” British Medical Journal2001; 322:82-85. [Doctors and nurses do not recommend it.]
  • BBC News. “Why Japan stopped using MMR,” (February 8, 2002).

Vaccino MPR  e meningite [statistiche]

  • Sugiura, A., et al. “Aseptic meningitis as a complication of mumps vaccination.” Journal of Pediatric Infectious Diseases 1991; 10:209-213. [1 case of meningitis per 2000 doses of mumps vaccine.]
  • Fujinaga, T., et al. “A prefecture-wide survey of mumps meningitis associated with measles, mumps and rubella vaccine.” Journal of Pediatric Infectious Diseases 1991; 10:204-209. [6 cases of meningitis per 2000 doses of mumps vaccine.]
  • Colville, A., et al. “Mumps meningitis and measles, mumps, and rubella vaccine.” Lancet 1992; 340:786. [1 case of meningitis per 3800 doses of mumps vaccine.]

Vaccino MPR e diabete

  • Sultz, H.A., et al. “Is mumps virus an etiologic factor in juvenile diabetes mellitus?” Journal of Pediatrics 1975; 86:654-656.
  • Sinaniotis, C.A., et al. “Diabetes mellitus after mumps vaccination (letter).” Archives of Disease in Childhood 1975; 50:749-750.
  • Quast, U., et al. “Vaccine-induced mumps-like diseases.” Developments in Biological Standardization 1979; 43:269-272.
  • Otten, A., et al. “Mumps, mumps vaccination, islet cell antibodies and the first manifestation of diabetes mellitus type I.” Behring Institute Mitteilungen 1984; 75:83-88.
  • Helmke, K., et al. “Islet cell antibodies and the development of diabetes mellitus in relation to mumps infection and mumps vaccination.” Diabetologia 1986; 29:30-33.
  • Fescharek, R., et al. “Measles-mumps vaccination in the FRG: an empirical analysis after 14 years of use. II. Tolerability and analysis of spontaneously reported side effects.” Vaccine 1990; 8:446-456.
  • Pawlowski, B., et al. “Mumps vaccination and type-1 diabetes.” Deutsche Medizinische Wochenschrift 1991; 116:635.
  • Adler, J.B., et al. “Pancreatitis caused by measles, mumps, and rubella vaccine.” Pancreas 1991; 6:489-490.
  • Albonico, H., Klein, P., et al. “The immunization campaign against measles, mumps and rubella — coercion leading to a realm of uncertainty: medical objections to a continued MMR immunization campaign in Switzerland.” JAM 1992; 9(1). [180 European medical doctors jointly noted that the mumps vaccine “can trigger diabetes, which only becomes apparent months after vaccination.”]

Il vaccino anti-morbillo [e trivalente MPR] associato a gravi disturbi ematici

  • Oski, F.A. and Naiman, J.L. “Effect of live measles vaccine on the platelet count.” New England Journal of Medicine 1966; 265:352-56.
  • Bottiger, M., et al. “Swedish experience of two dose vaccination programme aiming at eliminating measles, mumps, and rubella.” British Medical Journal 1987; 295:1264-67.
  • Koch, J. et al. “Adverse events temporally associated with immunizing agents 1987 report.” Canada Diseases Weekly Report 1989; 15:151-58.
  • Fescharek, R., et al. “Measles-mumps vaccination in the FRG: an empirical analysis after 14 years of use. II. Tolerability and analysis of spontaneously reported side effects.” Vaccine 1990; 8:446-56.
  • Nieminen, U., et al. “Acute thrombocytopenic purpura following measles, mumps and rubella vaccination: A report on 23 patients.” Acta Paediatrica 1993; 82:267-70.
  • 146. Farrington, P., et al. “A new method for active surveillance of adverse events from diphtheria/tetanus/pertussis and measles/mumps/rubella vaccines.” Lancet 1995; 345: 567-69.
  • Jonville-Bera, A.P., et al. “Thrombocytopenic purpura after measles, mumps, and rubella vaccination: a retrospective survey by the French Regional Pharmacovigilance Centres and Pasteur-Merieux Serums et Vaccins.” Pediatr Infect Dis J 1996; 15:44-48.
  • Beeler, J. et al. “Thrombocytopenia after immunization with measles vaccines: review of the Vaccine Adverse Events Reporting Systerm (1990-1994).” Pediatr Infect Dis J 1996; 15:88-90.

Il vaccino anti-morbillo [e trivalente MPR] associato a disfunzioni sensoriali [inclusi disturbi visivi e uditivi]

  • Kazarian, E.L., et al. “Optic neuritis complicating measles, mumps, and rubella vaccination.” American Journal of Ophthalmology 1978; 86:544-47.
  • Marshall, G.S., et al. “Diffuse retinopathy following measles, mumps, and rubella vaccination.” Pediatrics 1985; 76:989-991.
  • Brodsky, L., et al. “Sensorineural hearing loss following live measles virus vaccination.” International Journal of Pediatric Otorhinolaryngology 1985; 10:159-63.
  • Nabe-Nielsen, J., et al. “Unilateral deafness as a complication of the mumps, measles, and rubella vaccination.” British Medical Journal 1988; 297:489.
  • Hulbert, T.V., et al. “Bilateral hearing loss after measles and rubella vaccination in an adult.” New England Journal of Medicine 1991; 325:134.
  • Stewart, B.J.A., et al. “Reports of sensorineural deafness after measles, mumps, and rubella immunisation.” Archives of Diseases of Childhood 1993; 69:153-54.

Il vaccino anti-morbillo [e trivalente MPR] associato a disfunzioni immunitarie

  • Hirsch, R.L., et al. “Measles virus vaccination of measles seropositive individuals suppresses lymphocyte proliferation and chemotactic factor production.” Clinical Immunology and Immunopathology 1981; 21:341-50.
  • Nicholson, J.K.A., et al. “The effect of measles-rubella vaccination on lymphocyte populations and subpopulations in HIV-infected and healthy individuals.” Journal of Acquired Immune Deficiency Syndromes 1992; 5:528-537.

Il vaccino anti-morbillo [e trivalente MPR] associato a gravi reazioni allergiche

  • Aukrust, L., et al. “Severe hypersensitivity or intolerance reactions to measles vaccine in six children: clinical and immunological studies.” Allergy 1980; 35(7):581-87.
  • McEwen, J. “Early-onset reaction after measles vaccination: further Australian reports.” Medical Journal of Australia 1983; 2:503-505.
  • Koch, J., et al. “Adverse events temporally associated with immunizing agents 1987 report.” Canada Diseases Weekly Report 1989; 15:151-58.
  • Kelso, J.M., et al. “Anaphylaxis to measles, mumps, and rubella vaccine mediated by IgE to gelatin.” J Allergy Clin Immunol 1993; 91:867-72.
  • Sakaguchi, M., et al. “IgE antibody to gelatin in children with immediate-type reactions to measles and mumps vaccines.” J Allergy Clin Immunol 1995; 96:563-65.

Morbillo atipico

  • Cherry, J.D. “The ‘new’ epidemiology of measles and rubella.” Hospital Practice (July 1980), pp. 53-54.
  • Fulginiti, V.A., et al. “Altered reactivity to measles virus; atypical measles in children previously immunized with inactivated measles virus vaccines.” Journal of the American Medical Association 1967; 202:1075.
  • Martin, D.B., et al. “Atypical measles in adolescents and young adults.” Annals of Internal Medicine 1979; 90:877.
  • Gold, E. “Current progress in measles eradication in the United States.” Infect Med 1997; 14(4):297-300, 310.
  • Nichols, E.M. “Atypical measles: a continuing problem.” American Journal of Public Health 1979; 69(2):160-62.
  • Scott, T.F., et al. “Reactions to live-measles-virus vaccine in children previously inoculated with killed-virus vaccine.” New England Journal of Medicine 1967; 277(5):248-251.
  • Cherry, J.D., et al. “Atypical measles in children previously immunized with attenuated measles virus vaccines.” Pediatrics 1972; 50(5).
  • St. Geme, J.W., et al. “Exaggerated natural measles following attenuated virus immunization.” Pediatrics 1976; 57:148-150.
  • “Atypical measles syndrome.” Lancet 1979, pp. 962-963.

Vaccino anti morbillo [e MMR] associato a  malattie intestinali

  • Thompson, N.P., Wakefield, A.J, et al. “Is measles vaccination a risk factor for inflammatory bowel disease?” Lancet1995; 345:1071-1074.
  • Barton, J.R., et al. “Incidence of inflammatory bowel disease in Scottish children between 1968 and 1983: marginal fall in ulcerative colitis; three-fold rise in Crohn’s disease.” Gut1989; 30:618-622.
  • Whelan, G. “Epidemiology of inflammatory bowel disease.” Med Clin N Am1990; 74:1-12.
  • Ekbom, A., et al. “The role of perinatal measles infection in the aetiology of Crohn’s disease: a population-based epidemiological study.” Lancet1994; 334:508-510.
  • Miyamoto, H., et al. “Detection of immunoreactive antigen with monoclonal antibody to measles virus in tissue from patients with Crohn’s disease.” Journal of Gastroenterology1995; 30:28-33.
  • Wakefield, A.J., et al. “Evidence of persistent measles virus infection in Crohn’s disease.” Journal of Medical Virology1993; 39:345-53.
  • Wakefield, A.J., et al. “Crohn’s disease: pathogenesis and persistent measles virus infection.” Gastroenterology1995; 108:911-916.
  • Lewin, J., et al. “Confirmation of persistent measles virus infection of intestinal tissue by immunogold electron microscopy.” Gut 1995; 36:564-69.

Vaccino trivalente MMR [o monovalente anti-morbillo] associato a Autismo

  • Oleske, J. “Elevated rubeola [measles] titers in autistic children.” Abstract presented by D. Zecca and Dr. Graffino at an NIH meeting (September 23, 1997). As quoted by Richard Gallup in “Autismand autoimmunity.” www.chiroweb.com/archives/18/14/10.html (April 15, 2002.)
  • Fudenberg, H.H. “Dialysable lymphocyte extract (DlyE) in infantile onset autism: a pilot study.” Biotherapy1996; 9:143-147.
  • Gupta, S. “Immunology and immunologic treatment of autism.” Proceedings of the National Autism Association, Chicago 1996: 455-460.
  • Wakefield, A.J., et al. “Ileal-lymphoid-nodular hyperplasia, non-specific colitis, and pervasive developmental disorder in children.” Lancet1998; 351:637-641.
  • Yazbak, F.E. “Autism:Is there a vaccine connection? Part I. Vaccination after delivery.” 1999. www.garynull.com/documents/autism99b.htm
  • Yazbak, F.E. “Autism:Is there a vaccine connection? Part II. Vaccination around pregnancy.” 1999. www.garynull.com/documents/autism99b2.htm
  • Yazbak, F.E. “Autism:Is there a vaccine connection? Part III. Vaccination around pregnancy, the sequel.” 2000. www.garynull.com/documents/autism99b3.htm
  • Autism:Present Challenges, Future Needs — Why the Increased Rates?” Government Reform Committee Hearing, Washington, DC. (April 6, 2000.)
  • Autism:Why the Increased Rates? A One-Year Update.” Government Reform Committee Hearing, Washington, DC. (April 25-26, 2001.)
  • “The AutismEpidemic: Is the NIH and CDC Response Adequate?” Government Reform Committee Hearing, Washington, DC. (April 18, 2002.)
  • “The Status of Research into Vaccine Safety and Autism.” Government Reform Committee Hearing, Washington, DC. (June 19, 2002.)
  • Kawashima, K., et al. “Detection and sequencing of measles virus from peripheral mononuclear cells from patients with inflammatory bowel disease and autism.Digestive Diseases and Sciences(April 2000); 45:723-729.
  • Reuters Medical News. “Measles persistence confirmed in some patients with IBD, autisticenterocolitis.” (June 20, 2000). www.id.medscape.com/reuters/prof/2000/06/06.20/20000620scie001.html
  • Wakefield, A.J. et al. “Enterocolitis in children with developmental disorders.” American Journal of Gastroenterology2000; 95(9):2154-2156.
  • Wakefield, A., et al. “Measles, mumps and rubella vaccine: through a glass, darkly.” Adverse Drug Reaction and Toxicologica Reviews2000; 19(4):265-283.
  • Kiln MR,Autism, inflammatory bowel disease, and MMR vaccine.” Lancet1998 May 2;351(9112):1358.
  • Selway, “MMR vaccination and autism 1998. Medical practitioners need to give more than reassurance.” BMJ1998 Jun 13;316(7147):1824.
  • Nicoll A, Elliman D, Ross E, “MMR vaccination and autism 1998,” MJ1998 Mar 7;316(7133):715-716.
  • Lindley K J, Milla PJ, “Autism, inflammatory bowel disease, and MMR vaccine.”Lancet1998 Mar 21;351(9106):907-908.
  • Bedford H, et al, “Autism, inflammatory bowel disease, and MMR vaccine.” Lancet1998 Mar 21;351(9106):907.
  • Vijendra K. Singh, Sheren X. Lin, and Victor C. Yang, “Serological Association of Measles Virus and Human Herpesvirus-6 with Brain Autoantibodies in Autism,” Clinical Immunology and Immunopathology, Oct 1998, Vol. 89, No. 1, p 105-108.

Il vaccino anti morbillo è inefficace
[spesso si verificano focolai tra popolazioni altamente o pienamente vaccinate]

  • FDA. “FDA workshop to review warnings, use instructions, and precautionary information [on vaccines].” (Rockland, Maryland: FDA, September 18, 1992), p. 27.
  • Faich, G.A., et al. “Measles outbreak in Rhode Island.” Public Health Report1981 May-June; 96(3):264-266.
  • CDC. MMWR(February 1, 1985).
  • CDC. MMWR(June 1984).
  • CDC. MMWR(June 6, 1987).
  • Gustafson, T. “Measles outbreak in a fully immunized secondary school population.” New England Journal of Medicine1987; 316:771-74.
  • Markowitz, L.E., et al. “Patterns of transmission in measles outbreaks in the United States, 1985-1986.” New England Journal of Medicine1989; 320:75-81.
  • Robertson, S.E., et al. “A million dollar measles outbreak: epidemiology, risk factors, and a selective revaccination strategy.” Public Health Reports(January-February 1992), p. 24.
  • Edmonson, M.B., et al. “Mild measles and secondary vaccine failure during a sustained outbreak in a highly vaccinated population.” Journal of the American Medical Association1990; 263:2467-71.
  • Minnesota Department of Health. “Measles summary, 1987.”
  • CDC. “Measles.” MMWR1989; 38:329-330.
  • CDC. “Measles — Quebec.” MMWR1989; 38:329-30.
  • CDC. “Measles — United States, 1990.” MMWR1991; 40(2):369.
  • CDC. “U.S. Childhood Immunization Update: Measles.” (March 1997).
  • CDC. “Measles — United States, 1999.” MMWR 2000; 49(25): 557-560.

L’immunità naturale è superiore

  • CDC. “Babies of vaccinated moms more susceptible to measles.” Pediatrics(November 1999).
  • “Natural immunity to measles yields greater neutralizing capacity than vaccination.” Journal of Medical Virology 2000; 62:91-98.
  • Morbillo contro Morbillo

Il vaccino anti morbillo altera l’epidemiologia della malattia
[provoca tassi più elevati di morbillo in gruppi ad alto rischio]

  • Cherry, J.D. “The ‘new’ epidemiology of measles and rubella.” Hospital Practice(July 1980), p. 51.
  • Macgregor, J.D., et al. “Epidemic measles in Shetland during 1977 and 1978.” British Medical Journal1981; 282(6262):434-436.
  • Gold, E. “Current progress in measles eradication in the United States.” Infect Med1997; 14(4):297-300, 310.
  • CDC. “Measles — United States, 1999.” MMWR 2000; 49(25): 557-560.

Sperimentazioni sui bambini comprovano la mortalità del vaccino anti morbillo

  • Sabin, A.B., et al. “Successful immunization of children with and without maternal antibody by aerosolized measles vaccine. I. Different results with undiluted human diploid cell and chick embryo fibroblast vaccines.” JAMA1983; 249:2651-62.
  • Sabin, A.B., et al. “Successful immunization of children with and without maternal antibody by aerosolized measles vaccine. II. Vaccine comparisons and evidence for multiple antibody response.” JAMA1984; 251:2363-71.
  • Whittle, H.C., et al. “Immunisation of 4-6 month old Gambian infants with Edmonston-Zagreb measles vaccine.” Lancet1984; ii:834-37.
  • Whittle, H., et al. “Trial of high-dose Edmonston-Zagreb measles vaccine in The Gambia: antibody response and side-effects.” Lancet1988; ii:811-814.
  • Aaby, P., et al. “Trial of high-dose Edmonston-Zagreb measles vaccine in Guinea-Bissau: protective efficacy.” Lancet1988; i:809-811.
  • Garenne, M., et al. “Child mortality after high-titre measles vaccines: prospective study in Senegal.” Lancet1991; 338:903-907.
  • Whittle, H.C. “Effect of dose and strain of vaccine on success of measles vaccination of infants aged 4-5 months.” Lancet1988; i:963-66.
  • Khanum, S., et al. “Comparison of Edmonston-Zagreb and Schwartz strains of measles vaccine given by aerosol or subcutaneous injection.” Lancet1987; i:150-53.
  • Tidjani, O., et al. “Serological effects of Edmonston-Zagreb, Schwartz, and AIK-C measles vaccine strains given at ages 4-5 or 8-10 months.” Lancet1989; ii:1357-60.
  • Markowitz, L.E., et al. “Immunization of six-month-old infants with different doses of Edmonston-Zagreb and Schwartz measles vaccines.” New England Journal of Medicine1990; 332:580-87.
  • Awadu, K.O. Outrage! How Babies Were Used as Guinea Pigs in an L.A. County Vaccine Experiment.(Long Beach, CA: Conscious Rastra Press, 1996).

Parotite atipica

  • Gunby, P. “‘Atypical’ mumps may occur after immunization.” Journal of the American Medical Association 1980; 243(23): 2374-75.
  • Family Practice News (July 15, 1980), p. 1

Il vaccino contro la parotite è spesso inefficace e altera l’epidemiologia della malattia
[provoca tassi più elevati in gruppi ad alto rischio]

  • Fiumara, N.J., et al. “Mumps outbreak in Westwood, Massachusetts — 1981.” MMWR 1982; 33(29):421-430.
  • Kaplan, K.M., et al. “Further evidence of the changing epidemiology of a childhood vaccine-preventable disease.” Journal of the American Medical Association 1988; 260(10):1434-1438.
  • Briss, P. A., et al. “Sustained transmission of mumps in a highly vaccinated population: assessment of vaccine failure and waning vaccine-induced immunity.” Journal of Infectious Diseases 1994; 169:77-82.
  • Sawada, et al. Lancet 1993; 342:371.
  • CDC. “Mumps — United States, 1985-1988.” MMWR 1989; 38:101-05.

Ragazze che hanno contratto la parotite naturalmente durante l’infanzia hanno meno probabilità di sviluppare il cancro ovarico da adulte

  • West, R. “Epidemiologic study of malignancies of the ovaries.” Cancer 1966; 19:1001-1007.
  • Wynder, E., et al. “Epidemiology of cancer of the ovary.” Cancer 1969; 23:352.
  • Newhouse, M., et al. “A case control study of carcinoma of the ovary.” Brit J Prev Soc Med 1977; 31:148-53.
  • McGowan, L., et al. “The woman at risk from developing ovarian cancer.” Gynecol Oncol1979; 7:325-344.

Vaccini anti rosolia prodotti nei reni di cane e negli embrioni di anatra

  • Spruance, S.L., et al. “Recurrent joint symptoms in children vaccinated with HPV-77DK12 rubella vaccine.” Journal of Pediatrics1972;80(3):413-17.
  • Hilleman, M.R., et al. “Live attenuated rubella virus vaccines: experiences with duck embryo cell preparations.” American Journal of Diseases of Children1969; 118:166-171.
  • Cherry, J.D. “The ‘new’ epidemiology of measles and rubella.” Hospital Practice (July 1980), pp. 53-54.

Vaccini anti rosolia prodotti in tessuti polmonari di feti umani

  • Plotkin, S.A. “Development of RA 27/3 attenuated rubella virus grown in WI-38 cells.” Wistar Institute of Anatomy and Biology. Cited in International Symposium on Rubella Vaccines,London 1968; Symposium Series on Immunobiol. Standards (Karger, Basel/New York, 1969); 11:249-260.
  • Hayflick, L., et al. “The serial cultivation of human diploid cell strains.” Exp. Cell Res.1961; 25:585-621.
  • Plotkin, S.A., et al. “Studies of immunization with living rubella virus. Trials in children with a strain cultured from an aborted foetus.” Amer. J. Dis. Child.1965; 110:381-389.
  • Hoskins, J.M., et al. “Behaviour of rubella virus in human diploid cell strains. I. Growth of virus. II. Studies of infected cells.” Arch. ges. Virusforsch1967; 21:283-296.
  • Hayflick, L. “The limited in vitro lifetime of human diploid cell strains.” Exp. Cell Res.1965; 37:614-636.
  • Physician’s Desk Reference (PDR); 55th edition. (Montvale, NJ: Medical Economics, 2001), p. 1966.

Vaccino anti rosolia e artrite

  • Cooper, L.Z., et al. “Transient arthritis after rubella vaccination.” Am J Dis Child1969; 118:218-225.
  • Spruance, S.L., et al. “Joint complications associated with derivatives of HPV-77 rubella virus vaccine.” American Journal of Diseases in Children1971; 122:105-111.
  • Swartz, T.A., et al. “Clinical manifestations, according to age, among females given HPV-77 duck rubella vaccine.” American Journal of Epidemiology1971; 94:246-51.
  • Weibel, R.E., et al. “Influence of age on clinical response to HPV-77 duck rubella vaccine.” J. of American Medical Association1972; 222:805-807.
  • Thompson, G.R., et al. “Intermittent arthritis following rubella vaccination: a three year follow-up.” American Journal of Diseases of Children1973; 125:526-530.
  • Chantler, J.K., et al. “Persistent rubella infection and rubella-associated arthritis.” Lancet(June 12, 1982):1323-1325.
  • Tingle, A.J., et al. “Prolonged arthritis, viraemia, hypogamma-globulinaemia, and failed seroconversion following rubella immunisation.” Lancet1984; 1:1475-1476.
  • Tingle, A.J., et al. “Postpartum rubella immunization: association with development of prolonged arthritis, neurological sequelae, and chronic rubella viremia.” Journal of Infectious Diseases1985; 152:606-612.
  • Tingle, A.J., et al. “Rubella-associated arthritis. Comparative study of joint manifestations associated with natural rubella infection and RA 27/3 rubella immunisation.” Annals of the Rheumatic Diseases1986; 45:110-114.
  • Institute of Medicine. Adverse Effects of Pertussis and Rubella Vaccines.(Washington, DC: National Academy Press, 1991).
  • Benjamin, C.M., et al. “Joint and limb symptoms in children after immunisation with measles, mumps, and rubella vaccine.” British Medical Journal 1992; 304:1075-78.

Vaccino anti rosolia e disturbi neurologici

  • Kilroy, A.W., et al. “Two syndromes following rubella immunization.” Journal of the American Medical Association1970; 214:2287-2292.
  • Gilmarten, R.C., et al. “Rubella vaccine myeloradiculoneuritis.” Journal of Pediatrics1972; 80:406-412.
  • Schaffner, W., et al. “Polyneuropathy following rubella immunization: a follow-up study and review of the problem.” American Journal of Diseases of Children1974; 127:684-688.
  • Institute of Medicine. Adverse Effects of Pertussis and Rubella Vaccines.(Washington, DC: National Academy Press, 1991).
  • Muhlebach-Sponer, M., et al. “Intrathecal rubella antibodies in an adolescent with Guillain-Barre syndrome after mumps-measles-rubella vaccination.” European Journal of Pediatrics 1994; 154:166.

Vaccino anti rosolia e diabete

  • Menser, M., et al. “Rubella infection and diabetes mellitus.” Lancet(January 14, 1978), pp. 57-60.
  • Rayfield, E.J., et al. “Rubella virus-induced diabetes in the hamster.” Diabetes(December 1986); 35:1278-1281.
  • Ehrengut, W. “Central nervous system sequelae of immunization against measles, mumps, rubella and poliomyelitis.” Acta Paediatrica Japonica1990; 32:8-11.
  • Aubrey, J., et al. “Postpartum rubella immunization: association with development of prolonged arthritis, neurological sequelae, and chronic rubella viremia.” Journal of Infectious Diseases(September 1985); 152(3):606-612.
  • Coulter, Harris. “Childhood vaccinations and Juvenile-Onset (Type-1) diabetes.” Congressional Testimony. Committee on Appropriations, subcommittee on Labor, Health and Human Services, Education, and Related Agencies.(April 16, 1997).
  • Coyle, P.K., et al. “Rubella-specific immune complexes after congenital infection and vaccination.” Infection and Immunity(May 1982); 36(2):498-503.
  • Numazaki, K., et al. “Infection of cultured human fetal pancreatic islet cells by rubella virus.” American Journal of Clinical Pathology 1989; 91:446-451.

Vaccino anti rosolia e Sindrome da fatica cronica

  • Tobi, M., et al. “Prolonged atypical illness associated with serological evidence of persistent Epstein-Barr virus infection.” Lancet1982; 1:61-64.
  • Bicker, U. “Some new aspects of autoimmunity.” Journal of Immuno-pharmacology1986; 8:543-559.
  • Allen, A.D. “Is RA27/3 rubella immunization a cause of Chronic Fatigue?” Medical Hypotheses1988; 27:217-220.
  • Lieberman, A.D. “The role of the rubella virus in the chronic fatigue syndrome.” Clinical Ecology 1991; 7(3):51-54.

Vaccino anti rosolia e tassi di scarsa efficacia

  • Klock, L.E., et al. “Failure of rubella herd immunity during an epidemic.” New England Journal of Medicine1973; 288(2):69-72.
  • Allan, B. “Rubella immunisation.” Australian Journal of Medical Technology1973; 4:26-27.
  • Lawless, M., et al. “Rubella susceptibility in sixth-graders.” Pediatrics(June 1980); 65:1086-1089.
  • Bart, K.J., et al. “Universal immunization to interrupt rubella.” Review of Infectious Diseases1985; 7(1):S177-184.
  • Crowder, M., et al. “Rubella susceptibility in young women of rural East Texas: 1980 and 1985.” Texas Medicine1987; 83:43-47.
  • Fulginiti, V. “Controversies in current immunization policy and practices.” Current Problems in Pediatrics1976; 6:14.
  • Herrmann, K.L., et al. “Rubella antibody persistence after immunization.” Journal of the America Medical Association1982; 247(2):193-196.
  • Tingle, A.J., et al. “Failed rubella immunization in adults: association with immunologic and virological abnormalities.” Journal of Infectious Diseases 1985; 151(2):330-336.

Il vaccino anti rosolia altera l’epidemiologia della malattia
[provoca tassi più elevati di rosolia in gruppi ad alto rischio]

  • Cherry, J.D. “The ‘new’ epidemiology of measles and rubella.” Hospital Practice(July 1980), p. 55.
  • CDC. “Rubella and congenital rubella syndrome — United States, 1985-1988.” MMWR1989; 38:173-178.
  • CDC. “Current trends increase in rubella and congenital rubella syndrome — United States, 1988-1990.” MMWR Weekly (February 15, 1991); 40(6):93-99.

Medici rifiutano il vaccino anti rosolia

  • Mendelsohn, R. “Rubella shots for hospital employees.” The Doctor’s People: A Medical Newsletter for Consumers(Evanston, IL, August 1991):1-2.
  • Polk, B.F., et al. “An outbreak of rubella among hospital personnel.” New England Journal of Medicine1980;303:541-545.
  • Orenstein, W.A., et al. “Rubella vaccine and susceptible hospital employees: poor physician participation.” Journal of the American Medical Association(February 20, 1981); 245(7):711-713.
  • Sacks, J.J., et al. “Employee rubella screening program.” Journal of the American Medical Association 1983; 249:2675-2678
Annunci
Informazioni su Gabriele Milani 353 Articoli

infermiere, divenuto freelance per dovere di informazione, ma soprattutto padre di un bambino che ha presentato reazione avversa alla somministrazione dei vaccini anti-infettivi nella forma di ENCEFALOPATIA IMMUNO-ALLERGO-TOSSICA, che ha danneggiato lo sviluppo cerebrale ed evolutivo del bambino, sino a realizzare nel tempo il quadro clinico di disturbo autistico con grave deficit cognitivo.

2 Commenti

  1. Buonasera Valentina, grazie per i complimenti che [mi creda] in tutta sincerità avrei preferito evitare se solo le ASL informassero come loro dovere.

    MG